Akari Therapeutics, Plc has filed a prospectus related to the resale of up to 6 million American Depositary Shares (ADSs) representing 480 billion ordinary shares by the selling shareholders. This filing follows the company's recent capital raising activities, where it secured approximately $8.3 million in total capital during Q2 2026 through the completion of a private investment in public equity (PIPE) transaction and associated warrant exercises.

The PIPE offering generated gross proceeds of $5.5 million. Under the securities purchase agreement, the company agreed to sell and issue an aggregate of 1,470,588 ADSs or prefunded warrants to purchase ADSs. These were accompanied by Series H, Series I, and Series J warrants, with each series granting the right to purchase 1,470,588 ADSs. The issuance of these warrants remains subject to shareholder approval at the company's Annual General Meeting scheduled for June 30, 2026.

The $5.5 million in gross proceeds was originally structured to be funded in three separate tranches. The first tranche closed at the end of May 2026. The parties subsequently agreed to consolidate the second and third closings, initially scheduled for June and July 2026, into a single final closing event which occurred on June 26, 2026.

Separately, the company received approximately $2.8 million in additional proceeds during May 2026. This amount resulted from the exercise of warrants by investors participating in the PIPE transaction.

Funding Breakdown

Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, stated that the early completion of the funding and increased investor commitment provide added financial flexibility. The capital is intended to support the advancement of AKTX-101 and the company's proprietary PH1 RNA splicing modulator antibody drug conjugate (ADC) payload through potential strategic partnerships.